Altogether, our results demonstrate that low expression of NKX2‐1 fosters tumor growth, and targeting the CXCLs/CXCR2 axis with SB225002 mitigates the tumor growth induced by NKX2‐1 downregulation. The gene discussed is NKX2-1; the disease is neoplasm.